Abstract
Osteogenic sarcoma (osteosarcoma) is the most common primary tumor of bone. It accounts for approximately 19% of all malignant tumors of the bone. Of all the molecular targets altered during the genesis of osteosarcoma, the retinoblastoma gene (RB1) shows the highest frequency of inactivation. Published data from human osteosarcoma tumors and in vivo and in vitro model systems support a role for the retinoblastoma gene family in bone development and tumorigenesis. Although a variety of bone tumors, depending on the cell of origin, including osteoclasts or osteoclast-like cells, chondroblasts, and fibroblasts, are described, for the purpose of this review we will focus primarily on the tumors arising from the osteoblast lineage.
Keywords: Retinoblastoma tumor suppressor, osteosarcoma, osteoblast differentiation
Current Molecular Medicine
Title: The Retinoblastoma Protein in Osteoblast Differentiation and Osteosarcoma
Volume: 6 Issue: 7
Author(s): Amit Deshpande and Philip W. Hinds
Affiliation:
Keywords: Retinoblastoma tumor suppressor, osteosarcoma, osteoblast differentiation
Abstract: Osteogenic sarcoma (osteosarcoma) is the most common primary tumor of bone. It accounts for approximately 19% of all malignant tumors of the bone. Of all the molecular targets altered during the genesis of osteosarcoma, the retinoblastoma gene (RB1) shows the highest frequency of inactivation. Published data from human osteosarcoma tumors and in vivo and in vitro model systems support a role for the retinoblastoma gene family in bone development and tumorigenesis. Although a variety of bone tumors, depending on the cell of origin, including osteoclasts or osteoclast-like cells, chondroblasts, and fibroblasts, are described, for the purpose of this review we will focus primarily on the tumors arising from the osteoblast lineage.
Export Options
About this article
Cite this article as:
Deshpande Amit and Hinds W. Philip, The Retinoblastoma Protein in Osteoblast Differentiation and Osteosarcoma, Current Molecular Medicine 2006; 6 (7) . https://dx.doi.org/10.2174/1566524010606070809
DOI https://dx.doi.org/10.2174/1566524010606070809 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Genomic Approaches and Oxygen Radical Measurement as Biomarker Candidates of Off-Season Predictor of Pollinosis: A Pilot Study
Current Pharmacogenomics and Personalized Medicine Salmonella as Live Trojan Horse for Vaccine Development and Cancer Gene Therapy
Current Gene Therapy Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry Osteoporosis and its Association with Non-Gonadal Hormones Involved in Hypertension, Adiposity and Hyperglycaemia
Current Drug Targets Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry Gallic Acid Improved Amytryptiline Effect in Neuropathic Pain Induced by Partial Sciatic Nerve Ligation (PSNL) in Rats
The Natural Products Journal Dimethylaminoparthenolide, A Water Soluble Parthenolide, Suppresses Lung Tumorigenesis Through Down-Regulating the STAT3 Signaling Pathway
Current Cancer Drug Targets The Current and Future Therapies for Human Osteosarcoma
Current Cancer Therapy Reviews From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design Curcumin: Not So Spicy After All
Mini-Reviews in Medicinal Chemistry DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Preface
Current Cancer Drug Targets New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry Chemoresistance of Cancer Cells: Oncogenic Mutation of the p53 Tumor Suppressor Gene
Current Signal Transduction Therapy The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Phosphodiesterase 3 (PDE3): Structure, Localization and Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Constrained Analogs of Osteogenic Peptides
Current Medicinal Chemistry Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities
Current Topics in Medicinal Chemistry